Research programme: small molecule therapeutics - Sharp Edge Labs

Drug Profile

Research programme: small molecule therapeutics - Sharp Edge Labs

Alternative Names: chemical chaperone therapeutics

Latest Information Update: 26 Apr 2016

Price : $50

At a glance

  • Originator Sharp Edge Labs
  • Class Small molecules
  • Mechanism of Action Protein folding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease; Cystic fibrosis; Dementia; Lysosomal storage diseases; Parkinson's disease

Most Recent Events

  • 24 Mar 2016 Sharp Edge Labs and ORIG3N agree to co-develop small molecule therapeutics in USA for Alzheimer's disease, Cystic fibrosis, Dementia, Lysosomal storage diseases and Parkinson's disease
  • 24 Mar 2016 Sharp Edge Labs in-licenses Fluorogen Activating Module technology technology from Carnegie Mellon University before March 2016 (Sharp Edge Labs' website, March 2016)
  • 24 Mar 2016 Early research in Alzheimer's disease, Cystic fibrosis, Dementia, Lysosomal storage diseases, Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top